The therapeutic impact of manipulating microbiota in inflammatory bowel disease

Current Pharmaceutical Design

Volumn 15, Issue 18, 2009, Pages 2074-2086

  Kanauchi, Osamu ^a   Mitsuyama, Keiichi ^b   Andoh, Akira ^c  

^a KIRIN HOLDINGS CO LTD   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Butyrate; Crohn's disease; Microbiota; Prebiotics; Probiotics; Synbiotics; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; BETA DEFENSIN; BIFIDOGENIC GROWTH STIMULATOR; BUTYRIC ACID; CORTICOSTEROID; ESCHERICHIA COLI NISSLE 1917 EXTRACT; FRUCTOSE OLIGOSACCHARIDE; GERMINATED BARLEY FOODSTUFF; ISPAGULA; LACTOBACILLUS JOHNSONII LA1 EXTRACT; LACTOBACILLUS LACTIS EXTRACT; LACTOBACILLUS RHAMNOSUS GG EXTRACT; LACTOBACILLUS SALIVARIUS UCC118 EXTRACT; MESALAZINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; SACCHAROMYCES BOULARDII EXTRACT; SALAZOSULFAPYRIDINE; SYNBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VSL3;

ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; BACTERIAL CELL WALL; BIFIDOBACTERIUM LONGUM; BRAN; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; COLITIS; COLON CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENTERITIS; ESCHERICHIA COLI; GENETIC ENGINEERING; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DIET THERAPY; DIETARY SUPPLEMENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; PROBIOTICS;

EID: 68449086352     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788489195     Document Type: Review

References (122)

1. Munkholm P. Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(Suppl 2): 1-5.
2. Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006; 19(5): 475-84.
3. Sansonetti PJ, Di Santo JP. Debugging how bacteria manipulate the immune response. Immunity 2007; 26(2): 149-61.
4. Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003; 21(2): 105-28.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 417-29.
6. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: Lessons from animal models. J Gastroenterol 2008; 43(1): 1-17.
7. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001; 48(4): 526-35.
8. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53(12): 1813-6.
9. Comalada M, Bailon E, de Haro O, Lara-Villoslada F, Xaus J, Zarzuelo A, et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol 2006; 132(8): 487-97.
10. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 2002; 132(5): 1012-7.
11. D'Argenio G, Cosenza V, Delle Cave M, Iovino P, Delle Valle N, Lombardi G, et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 1996; 110(6): 1727-34.
12. Guarner F. The intestinal flora in inflammatory bowel disease: Normal or abnormal? Curr Opin Gastroenterol 2005; 21(4): 414-8.
13. Egert M, de Graaf AA, Smidt H, de Vos WM, Venema K. Beyond diversity: functional microbiomics of the human colon. Trends Microbiol 2006; 14(2): 86-91.
14. Guarner F. Malagelada JR, Gut flora in health and disease. Lancet 2003; 361(9356): 512-9.
15. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science 2005; 308(5728): 1635-8.
16. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006; 55(Pt 8): 1141-9.
17. Prindiville T, Cantrell M, Wilson KH. Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. Inflamm Bowel Dis 2004; 10(6): 824-33.
18. Seksik P, Sokol H, Lepage P, Vasquez N, Manichanh C, Mangin I, et al. Review article: The role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 (Suppl 3): 11-8.
19. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53(5): 685-93.
20. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000; 95(1 Suppl): S19-21.
21. Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17(4): 331-5.
22. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: An historical and analytic review. Inflamm Bowel Dis 1998; 4(1): 29-39.
23. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P, Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114(2): 262-7.
24. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K. Meyer zum Buschenfelde KH, Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102(3): 448-55.
25. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54(8): 1182-93.
26. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005; 206: 277-95.
27. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3): And TLR4 in inflammatory bowel disease. Infect Immun 2000; 68(12): 7010-7.
28. Inohara N, Nunez G.. NODs: Intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3(5): 371-82.
29. Eckmann L, Karin M. NOD2 and Crohn's disease: Loss or gain of function? Immunity 2005; 22(6): 661-7.
30. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006; 6(1): 9-20.
31. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124(4): 993-1000.
32. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF, Crohn's disease: A defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003; 15(6): 627-34.
33. Sartor RB, Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126(6): 1620-33.
34. Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19(10): 1073-8.
35. Cunliffe RN, Kamal M, Rose FR, James PD, Mahida YR, Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol 2002; 55(4): 298-304.
36. Deguchi Y, Andoh A, Inatomi O, Araki Y, Hata K, Tsujikawa T, et al. Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 2005; 16(4): 605-8.
37. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME, Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: Role for complement in inflammatory bowel disease. J Immunol 2004; 172(6): 3836-41.
38. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M, Antimicrobials in the management of inflammatory bowel disease. Digestion 2006; 73(Suppl 1): 77-85.
39. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91(2): 328-32.
40. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108(6): 1617-21.
41. Shanahan F, Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288(3): G417-21.
42. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80(Suppl 1): S147-71.
43. Reid G, Jass J, Sebulsky MT, McCormick JK, Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16(4): 658-72.
44. O'Sullivan GC, Kelly P, O'Halloran S, Collins C, Collins JK, Dunne C, et al. Probiotics: An emerging therapy. Curr Pharm Des 2005; 11(1): 3-10.
45. Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN, The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 2006; 8(6): 486-98.
46. Geier MS, Butler RN, Howarth GS, Inflammatory bowel disease: Current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007; 115(1): 1-11.
47. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T, The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 2005; 11(8): 1047-53.
48. Elson CO, From cheese to pharma: A designer probiotic for IBD. Clin Gastroenterol Hepatol 2006; 4(7): 836-7.
49. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126(5): 1358-73.
50. Otte JM, Podolsky DK, Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286(4): G613-26.
51. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121(3): 580-91.
52. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002; 8(6): 399-406.
53. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126(2): 520-8.
54. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100(7): 1539-46.
55. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13(8): 1103-8.
56. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study vs mesalamine. Gastroenterology 2000; 118: A781.
57. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infect Immun 2004; 72(10): 5750-8.
58. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A, Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18(1): 45-56.
59. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Gottl C, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11(2): 372-8.
60. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006; 74(7): 4075-82.
61. Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, et al. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005; 11(5): 455-63.
62. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT, Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354(9179): 635-9.
63. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617-23.
64. Malchow HA, Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25(4): 653-8.
65. Elmer GW, McFarland LV, Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001; 30(3): 837-54.
66. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131(6): 1812-25.
67. Guslandi M, Giollo P, Testoni PA, A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15(6): 697-8.
68. Guslandi M, Mezzi G, Sorghi M, Testoni PA, Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45(7): 1462-4.
69. Zhang L, Li N, Caicedo R, Neu J, Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr 2005; 135(7): 1752-6.
70. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003; 52(3): 370-6.
71. Veltkamp C, Tonkonogy SL, Schultz M, Sartor RB, Lactobacillus plantarum is superior to Lactobacillus GG in preventing colitis in IL-10 deficient mice. Gastroenterology 1999; 116(4): A838.
72. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23(11): 1567-74.
73. Gupta P, Andrew H, Kirschner BS, Guandalini S, Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31(4): 453-7.
74. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC, Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5.
75. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11(9): 833-9.
76. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C, Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002; 51(3): 405-9.
77. Corr SC, Li Y, Riedel CU, O'Toole P W, Hill C, Gahan CG, From the Cover: Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104(18): 7617-21.
78. Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O'Donoghue D, Kiely B, et al. A one year, randomised, double-blind, placebo controlled trial of a lactobacillus or a bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006; 130(Suppl 2): A-44.
79. McCarthy J, O'Mahony L, Dunne C, Kelly P, Feeney M, Kiely B, et al. An open trial of a novel probiotic as an alternative to steroids in mild/moderately active Crohn's Disease. Gut 2001; 49(Suppl3): A2447.
80. Vidal K, Donnet-Hughes A, Granato D, Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect Immun 2002; 70(4): 2057-64.
81. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S, Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000; 47(1): 79-87.
82. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55(6): 842-7.
83. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007; 13(2): 135-42.
84. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289(5483): 1352-5.
85. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127(2): 502-13.
86. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4(6): 754-9.
87. Gibson GR, Roberfroid MB, Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 1995; 125(6): 1401-12.
88. Macfarlane S, Macfarlane GT, Cummings JH, Review article: Prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006; 24(5): 701-14.
89. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A, Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005; 49(6): 601-8.
90. Kleessen B, Hartmann L, Blaut M, Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001; 86(2): 291-300.
91. Bovee-Oudenhoven IM, ten Bruggencate SJ, Lettink-Wissink ML, van der Meer R, Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats. Gut 2003; 52(11): 1572-8.
92. Campbell JM, Fahey GC, Jr. Wolf BW, Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr 1997; 127(1): 130-6.
93. Cherbut C, Michel C, Lecannu G, The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 2003; 133(1): 21-7.
94. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart BS, et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003; 90(1): 75-85.
95. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55(3): 348-55.
96. Mitsuyama K, Toyonaga A, Sata M, Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol 2002; 37(Suppl 14): 73-7.
97. Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003; 38(2): 134-41.
98. Fukuda M, Kanauchi O, Araki Y, Andoh A, Mitsuyama K, Takagi K, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: A comparison with probiotic or antibiotic treatment. Int J Mol Med 2002; 9(1): 65-70.
99. Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: A pilot study. Aliment Pharmacol Ther 1998; 12(12): 1225-30.
100. Kanauchi O, Iwanaga T, Mitsuyama K, Germinated barley foodstuff feeding. A novel neutraceutical therapeutic strategy for ulcerative colitis. Digestion 2001; 63(Suppl 1): 60-7.
101. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13(5): 643-7.
102. Isawa K, Hojo K, Yoda N, Kamiyama T, Makino S, Saito M, et al. Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3. Biosci Biotechnol Biochem 2002; 66(3): 679-81.
103. Okada Y, Tsuzuki Y, Miyazaki J, Matsuzaki K, Hokari R, Komoto S, et al. Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 2006; 55(5): 681-8.
104. Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: A pilot study. Nutrition 2006; 22(1): 76-81.
105. Marteau P, Flourie B, Cherbut C, Correze JL, Pellier P, Seylaz J, et al. Digestibility and bulking effect of ispaghula husks in healthy humans. Gut 1994; 35(12): 1747-52.
106. Rodriguez-Cabezas ME, Galvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr 2003; 22(5): 463-71.
107. Hallert C, Kaldma M, Petersson BG, Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991; 26(7): 747-50.
108. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94(2): 427-33.
109. Hallert C, Bjorck I, Nyman M, Pousette A, Granno C, Svensson H, Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis 2003; 9(2): 116-21.
110. Schrezenmeir J, de Vrese M, Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001; 73(2 Suppl): 361S-364S.
111. Bengmark S, Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metab Care 2001; 4(6): 571-9.
112. Haskey N, Dahl WJ, Synbiotic therapy: A promising new adjunctive therapy for ulcerative colitis. Nutr Rev 2006; 64(3): 132-8.
113. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil D A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005; 54(2): 242-9.
114. Hoentjen F, Welling GW, Harmsen HJ, Zhang X, Snart J, Tannock GW, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005; 11(11): 977-85.
115. Kanauchi O, Fukuda M, Matsumoto Y, Ishii S, Ozawa T, Shimizu M, et al. Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World J Gastroenterol 2006; 12(7): 1071-7.
116. Guarner F, Enteric flora in health and disease. Digestion 2006; 73 (Suppl 1): 5-12.
117. Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pradal G, et al. Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 2001; 48(1): 53-61.
118. Janne PA, Mayer RJ, Chemoprevention of colorectal cancer. N Engl J Med 2000; 342(26): 1960-8.
119. Kanauchi O, Mitsuyama K, Andoh A, Iwanaga T, Modulation of intestinal environment by prebiotic germinated barley foodstuff prevents chemo-induced colonic carcinogenesis in rats. Oncol Rep 2008; 20(4): 793-801.
120. Hatakka K, Saxelin M. Probiotics in intestinal and non-intestinal infectious diseases--clinical evidence. Curr Pharm Des 2008; 14(14): 1351-67.
121. Isolauri E, Kalliomaki M, Laitinen K, Salminen S. Modulation of the maturing gut barrier and microbiota: A novel target in allergic disease. Curr Pharm Des 2008; 14(14): 1368-75.
122. Motilva V, Talero E, Calvo JR, Villegas I, Alarcon-de-la-Lastra C, Sanchez-Fidalgo S. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des 2008; 14(1): 71-95.